An Open Label Extension Study to Assess the Long Term Safety and Efficacy of Dupilumab in Patients > 6months to < 18 years of age with Atopic Dermatitis

Project: Research project

Project Details

Description

An Open Label Extension Study to Assess the Long Term Safety and Efficacy of Dupilumab in Patients > 6 months to < 18 years of age with Atopic Dermatitis
StatusActive
Effective start/end date11/1/1711/30/22

Funding

  • Regeneron Pharmaceuticals, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.